Comparative Effectiveness Research

>Los Angeles, CA—Can comparative effectiveness research (CER) be used for determining value in cancer care? At the Fourth Annual Conference of the Association for Value-Based Cancer Care, C. Daniel Mullins, PhD, Chairman, Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, discussed this topic on the challenges of applying CER into value-based oncology therapy.

Los Angeles, CA—Comparative effectiveness research (CER) can be beneficial to determining value in cancer therapies, but challenges remain in applying this approach in oncology.

An interview with Brian Sweet, RPh, MBA

Even before enactment of national healthcare reform initiatives, development and implementation of a variety of comparative effectiveness research (CER) was well under way, even if it was not specifically called comparative effectiveness.

Washington, DC—Health information technology (IT) and informatics are fundamental to all comparative effectiveness research (CER), Amy Abernethy, MD, associate director of the Duke Comprehensive Medical Center and founder and director of the Duke Cancer Care Research Program, told attendees at a session of the American Association of Cancer Research (AACR) 101st Annual Meeting.

Baltimore, MD—Comparative effectiveness research (CER) is at the forefront of new cost-control efforts, according to experts speaking at a panel discussion at the Asso ciation of Community Cancer Centers’ (ACCC) 36th Annual National Meeting.